Plasma p-tau217 is an accurate blood-based biomarker of tau pathological brain changes in Down syndrome that could be used as a stand-alone blood-based biomarker or in combinations with age to help guide screening and enrichment strategies for inclusion of people with Down syndrome in future Alzheimer disease clinical trials. This evidence concerns the gene MAPT and Alzheimer disease.